151 related articles for article (PubMed ID: 16321868)
1. Intravascular lymphoma: a role for single-agent rituximab.
Bazhenova L; Higginbottom P; Mason J
Leuk Lymphoma; 2006 Feb; 47(2):337-41. PubMed ID: 16321868
[TBL] [Abstract][Full Text] [Related]
2. Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
Horváth B; Demeter J; Eros N; Hársing J; Csomor J; Matolcsy A; Bottlik G; Gyori G; Marschalkó M; Kárpáti S
J Am Acad Dermatol; 2009 Nov; 61(5):885-8. PubMed ID: 19632742
[TBL] [Abstract][Full Text] [Related]
3. Severe pulmonary complications after initial treatment with Rituximab for the Asian-variant of intravascular lymphoma.
Wu SJ; Chou WC; Ko BS; Tien HF
Haematologica; 2007 Jan; 92(1):141-2. PubMed ID: 17229654
[TBL] [Abstract][Full Text] [Related]
4. Intra-vascular large B-cell lymphoma revealed by a nephrotic syndrome: a one year remission induced by a high frequency CHOP and rituximab.
Girard T; Nochy D; Montravers F; Der Sahakian G; Fior R; Galanaud P; Boué F
Leuk Lymphoma; 2004 Aug; 45(8):1703-5. PubMed ID: 15370230
[TBL] [Abstract][Full Text] [Related]
5. Intravascular lymphoma presenting with cauda equina syndrome: treated with CHOP and rituxan.
Davis TS
Leuk Lymphoma; 2003 May; 44(5):887-8. PubMed ID: 12802932
[No Abstract] [Full Text] [Related]
6. [Intravascular lymphoma treated with anti CD20 monoclonal antibodies. Report of one case].
Alfaro J; Espinoza A; Manŕiquez M; Moyano L; González N; Larrondo M; Figueroa G
Rev Med Chil; 2004 Nov; 132(11):1403-6. PubMed ID: 15693204
[TBL] [Abstract][Full Text] [Related]
7. Intravascular lymphoma presenting as telangectasias: response to rituximab and combination chemotherapy.
Weichert G; Martinka M; Rivers JK
J Cutan Med Surg; 2003; 7(6):460-3. PubMed ID: 14605917
[TBL] [Abstract][Full Text] [Related]
8. Intravascular lymphoma masquerading as Vogt-Koyanagi-Harada syndrome.
Pahk PJ; Todd DJ; Blaha GR; Soukiasian SH; Landmann DS; Craven DE; Tronic BS; Zabar Y; Marx JL
Ocul Immunol Inflamm; 2008; 16(3):123-6. PubMed ID: 18569804
[TBL] [Abstract][Full Text] [Related]
9. Intravascular large B-cell lymphoma of the skin: typical clinical manifestations and a favourable response to rituximab-containing therapy.
Feldmann R; Schierl M; Sittenthaler M; Jahn R; Wogritsch C; Cerroni L; Steiner A; Breier F
Dermatology; 2009; 219(4):344-6. PubMed ID: 19590171
[TBL] [Abstract][Full Text] [Related]
10. Asian variant of intravascular lymphoma: aspects of diagnosis and the role of rituximab.
Shimizu I; Ichikawa N; Yotsumoto M; Sumi M; Ueno M; Kobayashi H
Intern Med; 2007; 46(17):1381-6. PubMed ID: 17827836
[TBL] [Abstract][Full Text] [Related]
11. Intravascular B-cell lymphoma: the role of skin biopsy.
Barnett CR; Seo S; Husain S; Grossman ME
Am J Dermatopathol; 2008 Jun; 30(3):295-9. PubMed ID: 18496438
[TBL] [Abstract][Full Text] [Related]
12. Intravascular large B-cell lymphoma as a cause of hypopituitarism: gradual and late reversal of hypopituitarism after long-term remission of lymphoma with immunochemotherapy.
Pekic S; Milicevic S; Colovic N; Colovic M; Popovic V
Endocrine; 2008; 34(1-3):11-6. PubMed ID: 18937075
[TBL] [Abstract][Full Text] [Related]
13. Primary cutaneous intravascular large B-cell lymphoma treated with combination chemotherapy and complicated by rituximab-induced interstitial lung disease.
Park GH; Kim CH; Chung WK; Won CH; Chang SE; Lee MW; Choi JH; Moon KC
Acta Derm Venereol; 2010 May; 90(3):296-8. PubMed ID: 20526551
[No Abstract] [Full Text] [Related]
14. [Intravascular lymphoma: two case reports demonstrating the heterogeneity of the disease].
Satzger I; Völker B; Kofahl-Krause D; Ganser A; Kapp A; Gutzmer R
Hautarzt; 2009 Feb; 60(2):131-6. PubMed ID: 18654750
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in heavily pretreated cutaneous B-cell lymphoma.
Zinzani PL; Stefoni V; Alinari L; Vianelli N; Baccarani M
Leuk Lymphoma; 2003 Sep; 44(9):1637-8. PubMed ID: 14565673
[No Abstract] [Full Text] [Related]
17. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma.
Matsuda I; Hirota S
Int J Clin Exp Pathol; 2015; 8(8):9737-41. PubMed ID: 26464748
[TBL] [Abstract][Full Text] [Related]
19. Tubulointerstitial capillaries limited intravascular lymphoma of the kidney.
Kimura Y; Takeuchi M; Matsue K
Int J Hematol; 2017 Nov; 106(5):589-590. PubMed ID: 28755205
[No Abstract] [Full Text] [Related]
20. Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report.
Jurczak W; Bryk AH; Mensah P; Gałązka K; Trofimiuk-Müldner M; Wyrobek Ł; Sawiec A; Skotnicki AB
J Med Case Rep; 2016 May; 10(1):123. PubMed ID: 27178351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
